Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Annalisa Chiappella, EHA 2018 – TP53 Mutations in DLBCL: the FIL-DLCL04 Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 20th 2018

Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle this.

1. Could you tell us a little about the FIL-DLCL04 study and its findings? (0:10)

2. What is the approximate percentage of patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation? (1:41)

3. What was the impact of TP53 mutations on the prognosis of these young patients with DLBCL? (3:03)

4. What treatment strategies are in clinical development for patients with DLBCL and a TP53 mutation? (4:01)

Speaker disclosures: Annalisa Chiappella has nothing to disclose in relation to this video interview.

Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup